

Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”



Andreas Schneeweiss ^{a,1}, Johannes Ettl ^{b,1}, Diana Lüftner ^c, Matthias W. Beckmann ^d, Erik Belleville ^e, Peter A. Fasching ^{d,*}, Tanja N. Fehm ^f, Matthias Geberth ^g, Lothar Häberle ^{d,h}, Peyman Hadji ⁱ, Andreas D. Hartkopf ^j, Carsten Hielscher ^k, Jens Huober ^l, Eugen Ruckhäberle ^f, Wolfgang Janni ^l, Hans Christian Kolberg ^m, Christian M. Kurbacher ⁿ, Evelyn Klein ^b, Michael P. Lux ^d, Volkmar Müller ^o, Naiba Nabieva ^d, Friedrich Overkamp ^p, Hans Tesch ^q, Elena Laakmann ^o, Florin-Andrei Taran ^j, Julia Seitz ^{a,r}, Christoph Thomssen ^s, Michael Untch ^t, Pauline Wimberger ^u, Rachel Wuerstlein ^v, Bernhard Volz ^d, Diethelm Wallwiener ^j, Markus Wallwiener ^r, Sara Y. Brucker ^j

^a National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany

^b Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany

^c Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany

^d Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany

^e ClinSol GmbH & Co KG, Würzburg, Germany

^f Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Germany

^g Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany

^h Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Erlangen, Germany

ⁱ Frankfurt Center of Bone Health Frankfurt, Germany

^j Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany

^k gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany

^l Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany

^m Marienhospital Bottrop, Bottrop, Germany

ⁿ Gynecology I (Gynecologic Oncology), Gynäkologisches Zentrum Bonn Friedensplatz, Bonn, Germany

^o Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany

^p Oncologianova GmbH, Recklinghausen, Germany

^q Oncology Practice at Bethanien Hospital, Frankfurt, Germany

^r Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany

^s Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany

^t Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany

^u National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Dresden University Hospital, Dresden, Germany

^v Department of Gynecology and Obstetrics, Breast Center, and CCC Munich, Munich University Hospital, Germany

In Fig. 2c and f of our publication Schneeweiss et al. [1] we mistakenly placed wrong Kaplan Meier Plots. In the attached figure this was corrected. All other estimates concerning the survival including the regression models are correct. We apologize for the mistake.

DOI of original article: <https://doi.org/10.1016/j.breast.2020.08.011>.

* Corresponding author. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen EMN, Friedrich Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054, Erlangen, Germany.

E-mail address: peter.fasching@uk-erlangen.de (P.A. Fasching).

¹ Shared co-authorship.

1. Schneeweiss A, Ettl J, Luftner D et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data


<https://doi.org/10.1016/j.breast.2020.12.007>

0960-9776/© 2020 The Author(s). Published by Elsevier Ltd. All rights reserved.


from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88–95.

Fig. 2. Progression-free survival (PFS) and overall survival (OS) for the total group analyzed. CDK4/6i, CDK4/6 inhibitors; ET, endocrine therapy; OS, overall survival; PFS, progression-free survival.


2a (PFS first-line setting)




2b (OS first-line setting)




2c (PFS second-line setting)



2d (OS second-line setting)



2e (PFS third-line setting)



2f (OS third-line setting)

